Secukinumab Response in Korean Patients with Moderate to Severe Plaque-Type Psoriasis Irrespective of Previous Biologic Use: 1-Year Experience at a Single Center

참고문헌 (6)

1. Leonardi CL, "Antibodies in the treatment of psoriasis : IL-12", 23 p40 and IL-17a, 2016, pp.35(4 Suppl 4), S74~S77
2. Blauvelt A, "Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year : results from the CLEAR study", J Am Acad Dermatol, 76, pp.60~69.e9 (2017)
3. Garnock-Jones KP, "Secukinumab : a review in moderate to severe plaque psoriasis", Am J Clin Dermatol, 16, pp.323~330 (2015)
4. 윤상웅, "건선치료에서의 최신 약물요법", 대한의사협회지, 62(3), pp.176~180 (2019), 대한의사협회
5. Kavanaugh A, "Efficacy of subcutaneous secukinumab in patients with active psoriatic arthritis stratified by prior tumor necrosis factor inhibitor use : results from the randomized placebo-controlled FUTURE 2 study", J Rheumatol, 43, pp.1713~1717 (2016)
6. Gottlieb AB, "Treatment outcomes with ixekizumab in patients with moderate-to-severe psoriasis who have or have not received prior biological therapies : an integrated analysis of two Phase III randomized studies", J Eur Acad Dermatol Venereol, 31, pp.679~685 (2017)

관련 논문AI추천